Atlas Trials

Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Clinical trial NCT02216084 · COMPLETED

Trial details

NCT number
NCT02216084
Sponsor
Baxalta now part of Shire
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Start date
2014-09-30
Primary completion
2016-02-22
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.